Log in

NASDAQ:TRILTrillium Therapeutics Stock Price, Forecast & News

$7.87
-0.23 (-2.84 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$7.78
Now: $7.87
$8.28
50-Day Range
$5.77
MA: $7.42
$9.43
52-Week Range
$0.24
Now: $7.87
$9.66
Volume893,225 shs
Average Volume1.58 million shs
Market Capitalization$656.67 million
P/E RatioN/A
Dividend YieldN/A
Beta2.2
Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trials for advanced hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; and TTI-2341, an epidermal growth factor receptor antagonist, which is in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 is headquartered in Mississauga, Canada.
Read More
Trillium Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.59 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TRIL
CUSIPN/A
Phone416-595-0627

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$120,000.00
Book Value($0.86) per share

Profitability

Net Income$-41,620,000.00

Miscellaneous

EmployeesN/A
Market Cap$656.67 million
Next Earnings Date8/11/2020 (Estimated)
OptionableOptionable

Receive TRIL News and Ratings via Email

Sign-up to receive the latest news and ratings for TRIL and its competitors with MarketBeat's FREE daily newsletter.

Trillium Therapeutics (NASDAQ:TRIL) Frequently Asked Questions

How has Trillium Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Trillium Therapeutics' stock was trading at $5.19 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TRIL stock has increased by 51.6% and is now trading at $7.87. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Trillium Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trillium Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Trillium Therapeutics.

When is Trillium Therapeutics' next earnings date?

Trillium Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Trillium Therapeutics.

How were Trillium Therapeutics' earnings last quarter?

Trillium Therapeutics Inc (NASDAQ:TRIL) issued its earnings results on Friday, May, 15th. The biotechnology company reported ($0.23) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.09) by $0.14. View Trillium Therapeutics' earnings history.

What price target have analysts set for TRIL?

3 brokers have issued 1 year price targets for Trillium Therapeutics' stock. Their forecasts range from $10.00 to $10.00. On average, they anticipate Trillium Therapeutics' share price to reach $10.00 in the next twelve months. This suggests a possible upside of 27.1% from the stock's current price. View analysts' price targets for Trillium Therapeutics.

Has Trillium Therapeutics been receiving favorable news coverage?

News headlines about TRIL stock have trended negative this week, according to InfoTrie Sentiment. The research group scores the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Trillium Therapeutics earned a daily sentiment score of -2.2 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the near future. View the latest news about Trillium Therapeutics.

Are investors shorting Trillium Therapeutics?

Trillium Therapeutics saw a drop in short interest during the month of June. As of June 15th, there was short interest totaling 5,850,000 shares, a drop of 5.2% from the May 31st total of 6,170,000 shares. Based on an average daily volume of 2,460,000 shares, the days-to-cover ratio is presently 2.4 days. Approximately 8.0% of the shares of the company are sold short. View Trillium Therapeutics' Current Options Chain.

Who are some of Trillium Therapeutics' key competitors?

What other stocks do shareholders of Trillium Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trillium Therapeutics investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Energy Transfer LP Unit (ET), Agile Therapeutics (AGRX), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Opko Health (OPK), TG Therapeutics (TGTX), Karyopharm Therapeutics (KPTI) and VBI Vaccines (VBIV).

Who are Trillium Therapeutics' key executives?

Trillium Therapeutics' management team includes the following people:
  • Dr. Bjorn Johan Niclas Stiernholm, Pres, CEO & Director
  • Mr. James T. Parsons C.A., C.P.A., MAcc, CPA-CA, Chief Financial Officer (Age 54)
  • Dr. Robert Uger, Chief Scientific Officer
  • Dr. Penka Petrova, Chief Devel. Officer
  • Dr. Yaping Shou, Chief Medical Officer

What is Trillium Therapeutics' stock symbol?

Trillium Therapeutics trades on the NASDAQ under the ticker symbol "TRIL."

How do I buy shares of Trillium Therapeutics?

Shares of TRIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Trillium Therapeutics' stock price today?

One share of TRIL stock can currently be purchased for approximately $7.87.

How big of a company is Trillium Therapeutics?

Trillium Therapeutics has a market capitalization of $656.67 million and generates $120,000.00 in revenue each year. The biotechnology company earns $-41,620,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis.

What is Trillium Therapeutics' official website?

The official website for Trillium Therapeutics is www.trilliumtherapeutics.com.

How can I contact Trillium Therapeutics?

Trillium Therapeutics' mailing address is 2488 DUNWIN DRIVE, MISSISSAUGA A6, L5L 1J9. The biotechnology company can be reached via phone at 416-595-0627 or via email at [email protected]

This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.